Accurate preoperative assessment of tumor stage and nuclear grade in clear cell renal cell carcinoma (ccRCC) is critical for surgical planning and patient counseling. Traditional imaging and biopsy approaches have limitations in capturing the full complexity of tumor biology across diverse patient populations.
Deep learning algorithms offer a data-driven approach to integrate clinical variables and predict pathological staging and grading from routinely collected preoperative data, potentially reducing the need for invasive procedures before definitive treatment.
This study evaluated three deep learning architectures, BiLSTM, CNN-BiLSTM, and CNN-BiGRU, applied to 22 preoperative clinical variables from 878 ccRCC patients at a single center, to determine which model most accurately predicted T-stage and G-grade classifications.
The study enrolled 878 patients diagnosed with ccRCC, split into a training set of 702 patients and a verification set of 176 patients. Twenty-two preoperative clinical variables were collected, including laboratory findings, imaging parameters, and patient demographics.
Three sequence-based deep learning models were compared: BiLSTM (Bidirectional Long Short-Term Memory), CNN-BiLSTM (Convolutional Neural Network combined with BiLSTM), and CNN-BiGRU (CNN combined with Bidirectional Gated Recurrent Unit). Each model captures temporal and contextual patterns across the clinical feature set.
The CNN layers extract local feature representations from the input variables, while the bidirectional recurrent layers capture dependencies in both forward and backward directions across the feature sequence, enabling richer representations of complex clinical data.
Model performance was evaluated using AUC (Area Under the Receiver Operating Characteristic Curve) separately for T-stage prediction and G-grade prediction on the held-out verification set.
For T-stage prediction, all three models performed strongly: BiLSTM achieved an AUC of 0.933, CNN-BiLSTM reached 0.947, and CNN-BiGRU attained the highest AUC at 0.948, indicating excellent discrimination between different tumor stages.
For G-grade prediction, a more challenging classification task, BiLSTM achieved an AUC of 0.754, CNN-BiLSTM scored 0.722, and CNN-BiGRU again outperformed the others with an AUC of 0.771. The CNN-BiGRU architecture consistently ranked best across both classification tasks.
The superior performance of CNN-BiGRU suggests that the combination of convolutional feature extraction and gated recurrent units with bidirectional processing offers a strong inductive bias for structured clinical tabular data in oncology settings.
Accurate preoperative T-stage prediction supports nephron-sparing surgery decisions, as patients with localized disease may be candidates for partial nephrectomy rather than radical resection. Models achieving AUC near 0.95 offer clinically meaningful discrimination for this decision.
G-grade classification, while harder to predict (AUC around 0.77), informs prognosis and post-operative surveillance intensity. Even modest improvements over standard clinical judgment could meaningfully impact resource allocation and patient follow-up schedules.
The 22-variable preoperative panel used here is composed of data routinely available before surgery, meaning implementation would not require additional invasive testing, lowering barriers to clinical adoption of deep learning-assisted staging.
CNN-BiGRU demonstrated the strongest and most consistent performance for predicting both pathological T-stage and G-grade in ccRCC using preoperative clinical variables, validating the utility of hybrid CNN-recurrent architectures for structured clinical data.
A key limitation of the study is its single-center design, which means the trained models reflect the patient population, imaging protocols, and clinical workflows of one institution. External validation across multiple centers is essential before clinical deployment.
Future work should focus on multicenter validation, incorporation of imaging-derived features such as radiomics, and prospective testing to confirm that these deep learning predictions translate into improved patient outcomes in routine clinical practice.